05 October 2022
Hogan Lovells released a survey that tracked the thinking of compliance professionals who are implementing ESG into compliance programs.
ESG (environmental, social and governance) has become a top compliance concern for life sciences companies around the world—yet the evidence suggests that many are struggling to embed ESG into their existing compliance programs.
A survey of compliance professionals at 100 multinational life sciences companies globally reveals an overwhelming majority—84%—report that ESG risk is increasing as a priority for their board. Yet more than four in five also report that the failure to embed ESG into existing risk practices is impeding their organization’s ESG risk management.
Hogan Lovells’ Navigating Deep Waters survey, released today, tracks the thinking of experienced compliance professionals who are integrating the social and governance aspects of ESG into existing compliance programs.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024